Dr Hanieh Khalili
Module leader in Pharmaceutical Science
Biotherapeutics development, formulation, characterisation. Ocular drug delivery., University of East London
Dr Khalili did her BSc and MSc in Chemistry and Analytical Chemistry in Iran. She then accomplished her PhD after completion of MSc in Drug Delivery at the UCL School of Pharmacy when she earned highest distinction on the MSc course. Her PhD was partially funded by PolyTherics for which the project was designed on PEGylation of antibody fragments (Fabs) using disulphide bridging method. Characterisation, conjugation and modification of several therapeutic antibodies (such as bevacizumab, trastuzumab, infliximab) were studied during her PhD studied. Dr Khalili did a postdoc research associate between UCL School of Pharmacy and Institute of Ophthalmology working with Profs Steve Brocchini and Sir Peng tee Khaw. The key focus of the post-doc was on development, and formulation of antibody mimetics such as bispecific antibodies and fusion proteins to modulate ocular healing after surgery and to develop dosage forms to inhibit inflammation, angiogenesis and fibrosis generally within the eye.
Module leader in Analytical Chemistry and Pharmaceutical Analysis
Member of Royal Society of Chemistry (MRSC)
Academy of Pharmaceutical Science (APS)
Antibody-based medicine including monoclonal antibodies, Fcfusion and scFv development, characterisation and formulation
Biotherapeutics formulation and stability determination
Bispecific antibody mimetic for ocular disease
UCL Institute of Ophthalmology
UCL School of Pharmacy
Protein Modification by Bis-alkylation
Christina Picken, Sahar Awwad, Mire Zloh, Hanieh Khalili, and Steve Brocchini. Oct 2020. Elsevier. Chapter 16.
Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF
H. Khalili P. T. Khaw, S. Brocchini, Sergey K. Filippov. 2018. RSC advance. 8: 35787.
A simple and rapid spectrophotometric method for the determination of ultra trace amounts of thallium (III) with 4-(4'-N,N-dimethylaminophenyl) urazole as a new reagent
Khalili, H., Rafiee, Z., Rezaei, B., Mallakpour, Sh.. 2005. Ann Chim. 897-903.
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Herrington-Symes, A., Farys, M., Khalili, H., Brocchini, S.. 2013. Advances in Bioscience and Biotechnology . 689-698.
Anti-TNFa antibody mimetic to treat ocular inflammation
H. Khalili, R. W. Lee, P. T. Khaw, S. Brocchini, A. Dick, D. Copland. 2016. Scientific Reports-Nature. 6: 36905..
Invited book; Chemical and genetic modification
Farys, M. Ginn, C, Badescu, G., Peciak, K, Pawlisz, E., Khalili, H., Brocchini, S.. 2013. Wiley.
Comparative binding of disulfide-bridged PEG-Fabs
Khalili, H., Godwin, A., Choi, J., Lever, R., Brocchini, S.. 2012. Bioconjugate Chemistry. 2262-2277.
Khalili, H., Godwin, A., Choi, J., Lever, R., Khaw, P. T., Brocchini, S. . 2013. Bioconjugate Chemistry. 1870-1882.
Khalili, H., Khaw, P. T., Brocchini, S. . 2016. Biomaterials Science.
PEGylation and its impact on the design of new protein-based medicines
Ginn, C., Khalili, H., lever, R., Brocchini, S.. 2014. Future Med Chem. 1829-1846.
Storage stability of bevacizumab in polycarbonate and polypropylene syringes
H.Khalili, G. Sharma. A. Froome, P.T. Khaw, S. Brocchini. 2015. Nature-eye. 820-827.
Fully funded PhD studentship, H. Khalili,£86,000 (2019); " Bispecific antibody mimetic for ocular inflammation"
Research funds, UEL, H. Khalili, £4,000 (2019); "High concentrated antibody mimetic for subcutaneous injection"
Early Research Career (ERC), H. Khalili, £8,000 (2016); "To Evaluate FpF stability and properties compared to IgGs"
CIF equipment funding,UCL, H. Khalili, S. Brocchini, £75,000, (2014) To Purchase equipments;
Research Innovation Fund, H. Khalili, UCL colleagues £10,000 (2013); " in-vivo study of antibody mimetics to treat ocular inflammation"
Biotherapeutics development and formulations
The main aim of this project is, therefore, to address the instability of protein of interest (such as aflibercept) at high concentrations. Different approaches are taken to address our aims such as lyophilisation method to stabilise proteins, hydrogel-based system for releasing of bioactive drug in a controlled and sustained manner.
Most approved antibody therapies are monospecific and are only able to bind to one target epitope. Bispecific therapies can potentially interact with two different targets to provide synergistic effects for greater clinical benefit than monospecific therapies. While there are 3 approved bispecific antibodies for oncology, none has been approved for ocular indication.
My research group has been working on development of novel bispecific antibody mimetic to treat ocular indications. This is a collaborative research with UCL School of Pharmacy.
Analytical Chemistry and Pharmaceutical Science
Module leader for MSc in Pharmaceutical Science;
Advanced Pharmaceutical Analysis and Quality Control Module leader for BSc in Chemistry;